Activation and regulation of interferon-β in immune responses

Immunologic Research

Volumn 53, Issue 1-3, 2012, Pages 25-40

  Sin, Wei Xiang ^a   Li, Peng ^a   Yeong, Joe Poh Sheng ^a   Chin, Keh Chuang ^a  

^a AGENCY FOR SCIENCE   (Singapore)

Author keywords

Interferon regulatory factors; Interferon ; Monocytes; Post translational modification; Transcriptional regulation

Indexed keywords

BETA INTERFERON; INTERFERON REGULATORY FACTOR 3; LIPOPOLYSACCHARIDE; VIRUS PROTEIN;

ADAPTIVE IMMUNITY; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; DENDRITIC CELL; GENE EXPRESSION REGULATION; HUMAN; INNATE IMMUNITY; INTERFERON PRODUCTION; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ADAPTIVE IMMUNITY; ANIMALS; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INTERFERON REGULATORY FACTOR-3; INTERFERON-BETA; PROTEIN PROCESSING, POST-TRANSLATIONAL; VIRAL PROTEINS;

EID: 84866742250     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-012-8293-7     Document Type: Article

References (182)

1. Isaacs A, Lindenmann J. Virus interference. 1. The interferon. P R Soc Lond B Biol. 1957;147:258-267.
2. Pestka S. The interferons: 50 years after their discovery, there is much more to learn. J Biol Chem. 2007;282:20047-51.
3. Friesen HJ, et al. Purification and molecular characterization of human fibroblast interferon. Arch Biochem Biophys. 1981;206: 432-50.
4. Rubinstein M, Rubinstein S, Familletti PC, Miller RS, Waldman AA, Pestka S. Human leukocyte interferon: production, purification to homogeneity, and initial characterization. Proc Natl Acad Sci U S A. 1979;76:640-4.
5. Stein S, Kenny C, Friesen HJ, Shively J, Del Valle U, Pestka S. NH2-terminal amino acid sequence of human fibroblast interferon. Proc Natl Acad Sci U S A. 1980;77:5716-9.
6. Borden EC, et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov. 2007;6:975-90.
7. de Andres C, et al. Interferon beta-1a therapy enhances CD4? regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis. J Neuroimmunol. 2007;182:204-11.
8. Ebers GC, et al. Long-term follow-up of the original interferonbeta1b trial in multiple sclerosis: design and lessons from a 16- year observational study. Clin Ther. 2009;31:1724-36.
9. Goodin DS, et al. Predictive value of baseline and short-term outcomes on mortality in multiple sclerosis: data from the interferon beta-1b 21-year long-term follow-up study. 21st Meeting of the European Neurological Society (ENS) 2011;Abstract P585.
10. Ebers GC, et al. Cause of death in patients with multiple sclerosis: the 21-year long-term follow-up study. 21st Meeting of the European Neurological Society (ENS) 2011;Abstracts P429.
11. Chiang EY, et al. Targeted depletion of lymphotoxin-alphaexpressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med. 2009;15:766-73.
12. Ito T, Amakawa R, Inaba M, Ikehara S, Inaba K, Fukuhara S. Differential regulation of human blood dendritic cell subsets by IFNs. J Immunol. 2001;166:2961-9.
13. Kito T, Kuroda E, Yokota A, Yamashita U. Enhancement of macrophage cytotoxicity against murine gliomas by interferon beta: increase in nitric oxide production in response to gliomaderived soluble factors. J Neurosurg. 2002;97:619-26.
14. Longhi MP, et al. Dendritic cells require a systemic type I interferon response to mature and induce CD4? Th1 immunity with poly IC as adjuvant. J Exp Med. 2009;206:1589-602.
15. Nguyen KB, et al. Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection. J Immunol. 2002;169:4279-87.
16. Su L, David M. Inhibition of B cell receptor-mediated apoptosis by IFN. J Immunol. 1999;162:6317-21.
17. Sing A, et al. Bacterial induction of beta interferon in mice is a function of the lipopolysaccharide component. Infect Immun. 2000;68:1600-7.
18. Parker D, Prince A. Type I interferon response to extracellular bacteria in the airway epithelium. Trends Immunol. 2011; 32:582-8.
19. Perry AK, Chen G, Zheng D, Tang H, Cheng G. The host type I interferon response to viral and bacterial infections. Cell Res. 2005;15:407-22.
20. Mancuso G, et al. Type I IFN signaling is crucial for host resistance against different species of pathogenic bacteria. J Immunol. 2007;178:3126-33.
21. Utaisincharoen P, Anuntagool N, Limposuwan K, Chaisuriya P, Sirisinha S. Involvement of beta interferon in enhancing inducible nitric oxide synthase production and antimicrobial activity of Burkholderia pseudomallei-infected macrophages. Infect Immun. 2003;71:3053-7.
22. Gautier G, et al. A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J Exp Med. 2005;201:1435-46.
23. Decker T, Muller M, Stockinger S. The yin and yang of type I interferon activity in bacterial infection. Nat Rev Immunol. 2005;5:675-87.
24. Mahieu T, Libert C. Should we inhibit type I interferons in sepsis? Infect Immun. 2007;75:22-9.
25. O'Connell RM, et al. Type I interferon production enhances susceptibility to Listeria monocytogenes infection. J Exp Med. 2004;200:437-45.
26. Thomas KE, Galligan CL, Newman RD, Fish EN, Vogel SN. Contribution of interferon-beta to the murine macrophage response to the toll-like receptor 4 agonist, lipopolysaccharide. J Biol Chem. 2006;281:31119-30.
27. Zwaferink H, Stockinger S, Hazemi P, Lemmens-Gruber R, Decker T. IFN-b increases listeriolysin O-induced membrane permeabilization and death of macrophages. J Immunol. 2008; 180:4116-23.
28. Carrero JA, Calderon B, Unanue ER. Type I interferon sensitizes lymphocytes to apoptosis and reduces resistance to listeria infection. J Exp Med. 2004;200:535-40.
29. Al Moussawi K, Ghigo E, Kalinke U, Alexopoulou L, Mege J-L, Desnues B. Type I interferon induction is detrimental during infection with the Whipple's disease bacterium, Tropheryma whipplei. Plos Pathog. 2010;6:e1000722.
30. Herskovits AA, Auerbuch V, Portnoy DA. Bacterial ligands generated in a phagosome are targets of the cytosolic innate immune system. Plos Pathog. 2007;3:e51.
31. Gruenberg J, van der Goot FG. Mechanisms of pathogen entry through the endosomal compartments. Nat Rev Mol Cell Biol. 2006;7:495-504.
32. Pandey AK, et al. NOD2, RIP2 and IRF5 play a critical role in the type I interferon response to Mycobacterium tuberculosis. PLoS Pathog. 2009;5:e1000500.
33. Takaoka A, et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature. 2007;448:501-5.
34. Hornung V, et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature. 2009; 458:514-8.
35. Roberts TL, et al. HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA. Science. 2009;323: 1057-60.
36. Yang P, et al. The cytosolic nucleic acid sensor LRRFIP1 mediates the production of type I interferon via a beta-catenindependent pathway. Nat Immunol. 2010;11:487-94.
37. Sabbah A, et al. Activation of innate immune antiviral responses by Nod2. Nat Immunol. 2009;10:1073-80.
38. Wang ZC, et al. Regulation of innate immune responses by DAI (DLM-1/ZBP1) and other DNA-sensing molecules. Proc Natl Acad Sci U S A. 2008;105:5477-82.
39. Lippmann J, et al. IFNb responses induced by intracellular bacteria or cytosolic DNA in different human cells do not require ZBP1 (DLM-1/DAI). Cell Microbiol. 2008;10:2579-88.
40. Burckstummer T, et al. An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat Immunol. 2009;10:266-72.
41. Ludlow LEA, Johnstone RW, Clarke CJP. The HIN-200 family: more than interferon-inducible genes? Exp Cell Res. 2005;308: 1-17.
42. Unterholzner L, et al. IFI16 is an innate immune sensor for intracellular DNA. Nat Immunol. 2010;11:997-1004.
43. Kim YG, et al. Viral infection augments Nod1/2 signaling to potentiate lethality associated with secondary bacterial infections. Cell Host Microbe. 2011;9:496-507.
44. Hu JZ, et al. Role of cell-to-cell variability in activating a positive feedback antiviral response in human dendritic cells. Plos One 2011;6:e16614.
45. Guarda G, et al. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity. 2011;34:213-23.
46. O'Riordan M, Yi CH, Gonzales R, Lee KD, Portnoy DA. Innate recognition of bacteria by a macrophage cytosolic surveillance pathway. Proc Natl Acad Sci U S A. 2002;99:13861-6.
47. Mocci S, Dalrymple SA, Nishinakamura R, Murray R. The cytokine stew and innate resistance to L-monocytogenes. Immunol Rev. 1997;158:107-14.
48. Sen GC. Viruses and interferons. Annu Rev Microbiol. 2001; 55:255-81.
49. Tailor P, Tamura T, Ozato K. IRF family proteins and type I interferon induction in dendritic cells. Cell Res. 2006;16:134-40.
50. Mancuso G, et al. Bacterial recognition by TLR7 in the lysosomes of conventional dendritic cells. Nat Immunol. 2009;10: 587-94.
51. Scheu S, Dresing P, Locksley RM. Visualization of IFNbeta production by plasmacytoid versus conventional dendritic cells under specific stimulation conditions in vivo. Proc Natl Acad Sci U S A. 2008;105:20416-21.
52. Cervantes-Barragan L, et al. Control of coronavirus infection through plasmacytoid dendritic-cell-derived type I interferon. Blood. 2007;109:1131-7.
53. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity. 2001;14:461-70.
54. Lindahl P, Gresser I, Leary P, Tovey M. Interferon treatment of mice: enhanced expression of histocompatibility antigens on lymphoid cells. Proc Natl Acad Sci U S A. 1976;73:1284-7.
55. Santini SM, et al. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med. 2000;191:1777-88.
56. Luft T, et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol. 1998;161:1947-53.
57. Wenner CA, Guler ML, Macatonia SE, O'Garra A, Murphy KM. Roles of IFN-gamma and IFN-alpha in IL-12-induced T helper cell-1 development. J Immunol. 1996;156:1442-7.
58. Ito T, et al. Plasmacytoid dendritic cells regulate Th cell responses through OX40 ligand and type I IFNs. J Immunol. 2004;172:4253-9.
59. Huber JP, Farrar JD. Regulation of effector and memory T-cell functions by type I interferon. Immunology. 2011;132:466-74.
60. Kastenmuller K, et al. Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets. J Clin Invest. 2011;121:1782-96.
61. Nguyen-Pham TN, et al. Type I and II interferons enhance dendritic cell maturation and migration capacity by regulating CD38 and CD74 that have synergistic effects with TLR agonists. Cell Mol Immunol. 2011;8:341-7.
62. Rajagopal D, Paturel C, Morel Y, Uematsu S, Akira S, Diebold SS. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists. Blood. 2010;115:1949-57.
63. Nagai T, Devergne O, Mueller TF, Perkins DL, van Seventer JM, van Seventer GA. Timing of IFN-beta exposure during human dendritic cell maturation and naive Th cell stimulation has contrasting effects on Th1 subset generation: a role for IFNbeta- mediated regulation of IL-12 family cytokines and IL-18 in naive Th cell differentiation. J Immunol. 2003;171:5233-43.
64. Longman RS, Braun D, Pellegrini S, Rice CM, Darnell RB, Albert ML. Dendritic-cell maturation alters intracellular signaling networks, enabling differential effects of IFN-alpha/beta on antigen cross-presentation. Blood. 2007;109:1113-22.
65. Nagai T, Devergne O, van Seventer GA, van Seventer JM. Interferon-beta mediates opposing effects on interferon-gammadependent Interleukin-12 p70 secretion by human monocytederived dendritic cells. Scand J Immunol. 2007;65:107-17.
66. Korporal M, et al. Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells. Arch Neurol-Chicago 2008;65:1434-1439.
67. Martin-Saavedra FM, Gonzalez-Garcia C, Bravo B, Ballester S. Beta interferon restricts the inflammatory potential of CD4? cells through the boost of the Th2 phenotype, the inhibition of Th17 response and the prevalence of naturally occurring T regulatory cells. Mol Immunol. 2008;45:4008-19.
68. Zhang X, Markovic-Plese S. Interferon beta inhibits the Th17 cell-mediated autoimmune response in patients with relapsingremitting multiple sclerosis. Clin Neurol Neurosurg. 2010;112: 641-5.
69. Axtell RC, et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med. 2010;16:406-12.
70. Steegmann JL, et al. Interferon alpha for chronic myeloid leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1999;23:483-8.
71. Streetly M, Kazmi M, Radia D, Hoyle C, Schey SA. Second autologous transplant with cyclosporin/interferon alpha-induced graft versus host disease for patients who have failed first-line consolidation. Bone Marrow Transplant. 2004;33:1131-5.
72. Porter DL, Roth MS, Mcgarigle C, Ferrara JLM, Antin JH. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid-leukemia. N Engl J Med. 1994; 330:100-6.
73. Thornley TB, et al. Type 1 IFN mediates cross-talk between innate and adaptive immunity that abrogates transplantation tolerance. J Immunol. 2007;179:6620-9.
74. Serrano J, Prieto E, Mazarbeitia F, Roman A, Llamas P, Tomas JF. Atypical chronic graft-versus-host disease following interferon therapy for chronic myeloid leukaemia relapsing after allogeneic BMT. Bone Marrow Transplant. 2001;27:85-7.
75. Robb RJ, et al. Type I-IFNs control GVHD and GVL responses after transplantation. Blood. 2011;118:3399-409.
76. Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity. 1998;8:363-72.
77. Ruuth K, Carlsson L, Hallberg B, Lundgren E. Interferon-alpha promotes survival of human primary B-lymphocytes via phosphatidylinositol 3-kinase. Biochem Biophys Res Commun. 2001;284:583-6.
78. Oka H. Regulation of human B-cell responsiveness by interferon- alpha-interferon-alpha-mediated suppression of B-cell function is reversed through direct interactions between monocytes and B-cells. Cell Immunol. 1993;146:238-48.
79. Braun D, Caramalho I, Demengeot J. IFN-a/b enhances BCRdependent B cell responses. Int Immunol. 2002;14:411-9.
80. Jego G, Palucka AK, Blanck J-P, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through Type I interferon and interleukin 6. Immunity. 2003;19:225-34.
81. Niewold TB, Clark DN, Salloum R, Poole BD. Interferon alpha in systemic lupus erythematosus. J Biomed Biotechnol. 2010; 2010:948364.
82. Thibault DL, Graham KL, Lee LY, Balboni I, Hertzog PJ, Utz PJ. Type I interferon receptor controls B-cell expression of nucleic acid-sensing Toll-like receptors and autoantibody production in a murine model of lupus. Arthritis Res Ther. 2009; 11:R112.
83. de Goer de Herve MG, et al. Interferon-alpha triggers B cell effector 1 (Be1) commitment. Plos One 2011;6:e19366.
84. Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol. 2005;23:307-36.
85. Kang JY, Lee JO. Structural biology of the Toll-like receptor family. Annu Rev Biochem. 2011;80:917-41.
86. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4:499-511.
87. Fitzgerald KA, et al. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol. 2003;4: 491-6.
88. Sharma S, tenOever BR, Grandvaux N, Zhou GP, Lin R, Hiscott J. Triggering the interferon antiviral response through an IKKrelated pathway. Science. 2003;300:1148-51.
89. Uze G, Schreiber G, Piehler J, Pellegrini S. The receptor of the type I interferon family. Curr Top Microbiol Immunol. 2007; 316:71-95.
90. Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem. 2007;282:20059-63.
91. Mariathasan S, Weiss DS, Dixit VM, Monack DM. Innate immunity against Francisella tularensis is dependent on the ASC/caspase-1 axis. J Exp Med. 2005;202:1043-9.
92. Henry T, Brotcke A, Weiss DS, Thompson LJ, Monack DM. Type I interferon signaling is required for activation of the inflammasome during Francisella infection. J Exp Med. 2007; 204:987-94.
93. Mariathasan S, et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature. 2006;440:228-32.
94. Lara-Tejero M, et al. Role of the caspase-1 inflammasome in Salmonella typhimurium pathogenesis. J Exp Med. 2006;203: 1407-12.
95. Fernandes-Alnemri T, et al. The AIM2 inflammasome is critical for innate immunity to Francisella tularensis. Nat Immunol. 2010;11:385-93.
96. Stetson DB, Medzhitov R. Type I interferons in host defense. Immunity. 2006;25:373-81.
97. Jiang Z, Mak TW, Sen G, Li X. Toll-like receptor 3-mediated activation of NF-kappaB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter inducing IFN-beta. Proc Natl Acad Sci U S A. 2004;101:3533-8.
98. Han KJ, Su X, Xu LG, Bin LH, Zhang J, Shu HB. Mechanisms of the TRIF-induced interferon-stimulated response element and NF-kappaB activation and apoptosis pathways. J Biol Chem. 2004;279:15652-61.
99. Ning S, Pagano JS, Barber GN. IRF7: activation, regulation, modification and function. Genes Immun. 2011;12:399-414.
100. Dai P, et al. Myxoma virus induces type I interferon production in murine plasmacytoid dendritic cells via a TLR9/MyD88-, IRF5/ IRF7-, and IFNAR-dependent pathway. JVirol. 2011;85:10814-25.
101. Smale ST, Fisher AG. Chromatin structure and gene regulation in the immune system. Annu Rev Immunol. 2002;20:427-62.
102. Panne D, Maniatis T, Harrison SC. An atomic model of the interferon-beta enhanceosome. Cell. 2007;129:1111-23.
103. Ford E, Thanos D. The transcriptional code of human IFN-b gene expression. Biochimica et Biophysica Acta (BBA)-Gene Regul Mech. 2010;1799:328-336.
104. Apostolou E, Thanos D. Virus infection induces NF-kappaBdependent interchromosomal associations mediating monoallelic IFN-beta gene expression. Cell. 2008;134:85-96.
105. Li P, et al. IRF8 and IRF3 cooperatively regulate rapid interferon- beta induction in human blood monocytes. Blood. 2011;117:2847-54.
106. Driggers PH, et al. An interferon gamma-regulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I genes. Proc Natl Acad Sci U S A. 1990;87:3743-7.
107. Wang T, Town T, Alexopoulou L, Anderson JF, Fikrig E, Flavell RA. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med. 2004;10:1366-73.
108. Hemmi H, et al. The roles of two IkappaB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection. J Exp Med. 2004;199:1641-50.
109. Krug A, Luker GD, Barchet W, Leib DA, Akira S, Colonna M. Herpes simplex virus type 1 activates murine natural interferonproducing cells through toll-like receptor 9. Blood. 2004;103: 1433-7.
110. Lund J, Sato A, Akira S, Medzhitov R, Iwasaki A. Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med. 2003;198:513-20.
111. Yoneyama M, et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol. 2004;5:730-7.
112. Nasirudeen AM, Wong HH, Thien P, Xu S, Lam KP, Liu DX. RIG-I, MDA5 and TLR3 synergistically play an important role in restriction of dengue virus infection. PLoS Negl Trop Dis. 2011;5:e926.
113. Hogle JM. Poliovirus cell entry: common structural themes in viral cell entry pathways. Annu Rev Microbiol. 2002;56:677-702.
114. Rohde K, Yates RM, Purdy GE, Russell DG. Mycobacterium tuberculosis and the environment within the phagosome. Immunol Rev. 2007;219:37-54.
115. Sirard JC, Vignal C, Dessein R, Chamaillard M. Nod-like receptors: cytosolic watchdogs for immunity against pathogens. PLoS Pathog. 2007;3:e152.
116. Girardin SE, et al. Peptidoglycan molecular requirements allowing detection by Nod1 and Nod2. J Biol Chem. 2003; 278:41702-8.
117. van der Wel N, et al. M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell. 2007;129:1287-98.
118. Qiao Y, et al. Host defense responses to infection by Mycobacterium tuberculosis. Induction of IRF-1 and a serine protease inhibitor. J Biol Chem. 2002;277:22377-85.
119. Stetson DB, Medzhitov R. Recognition of cytosolic DNA activates an IRF3-dependent innate immune response. Immunity. 2006;24:93-103.
120. Clark IA, Alleva LM, Mills AC, Cowden WB. Pathogenesis of malaria and clinically similar conditions. Clin Microbiol Rev. 2004;17:509-39.
121. Voisine C, Mastelic B, Sponaas AM, Langhorne J. Classical CD11c? dendritic cells, not plasmacytoid dendritic cells, induce T cell responses to Plasmodium chabaudi malaria. Int J Parasitol. 2010;40:711-9.
122. Khor CC, et al. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet. 2007;39:523-8.
123. Parroche P, et al. Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9. Proc Natl Acad Sci U S A. 2007; 104:1919-24.
124. Sharma S, et al. Innate immune recognition of an AT-rich stemloop DNA motif in the Plasmodium falciparum genome. Immunity. 2011;35:194-207.
125. Sozzani S, Type I. Interferons in systemic autoimmunity. Autoimmunity. 2010;43:196-203.
126. Salloum R, Niewold TB. Interferon regulatory factors in human lupus pathogenesis. Transl Res. 2011;157:326-31.
127. Ye J, Maniatis T. Negative regulation of interferon-b gene expression during acute and persistent virus infections. PLoS ONE. 2011;6:e20681.
128. Sathish N, Yuan Y. Evasion and subversion of interferon-mediated antiviral immunity by Kaposi's sarcoma-associated herpesvirus: an overview. J Virol. 2011;85:10934-44.
129. Rezaee SAR, Cunningham C, Davison AJ, Blackbourn DJ. Kaposi's sarcoma-associated herpesvirus immune modulation: an overview. J Gen Virol. 2006;87:1781-804.
130. Sathish N, Zhu FX, Golub EE, Liang Q, Yuan Y. Mechanisms of autoinhibition of IRF-7 and a probable model for inactivation of IRF-7 by Kaposi's sarcoma-associated herpesvirus protein ORF45. J Biol Chem. 2011;286:746-56.
131. Zhu FX, King SM, Smith EJ, Levy DE, Yuan Y. A Kaposi's sarcoma- associated herpesviral protein inhibits virus-mediated induction of type I interferon by blocking IRF-7 phosphorylation and nuclear accumulation. Proc Natl Acad Sci U S A. 2002;99:5573-8.
132. Yu Y, Wang SE, Hayward GS. The KSHV immediate-early transcription factor RTA encodes ubiquitin E3 ligase activity that targets IRF7 for proteosome-mediated degradation. Immunity. 2005;22:59-70.
133. Lin R, et al. HHV-8 encoded vIRF-1 represses the interferon antiviral response by blocking IRF-3 recruitment of the CBP/ p300 coactivators. Oncogene. 2001;20:800-11.
134. Joo CH, Shin YC, Gack M, Wu L, Levy D, Jung JU. Inhibition of interferon regulatory factor 7 (IRF7)-mediated interferon signal transduction by the Kaposi's sarcoma-associated herpesvirus viral IRF homolog vIRF3. J Virol. 2007;81:8282-92.
135. Lefort S, Soucy-Faulkner A, Grandvaux N, Flamand L. Binding of Kaposi's sarcoma-associated herpesvirus K-bZIP to interferon- responsive factor 3 elements modulates antiviral gene expression. J Virol. 2007;81:10950-60.
136. Hwang S, et al. Conserved herpesviral kinase promotes viral persistence by inhibiting the IRF-3-mediated type I interferon response. Cell Host Microbe. 2009;5:166-78.
137. Cloutier N, Flamand L. Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen inhibits interferon (IFN) b expression by competing with IFN regulatory factor-3 for binding to IFNB promoter. J Biol Chem. 2010;285:7208-21.
138. Bentz GL, Liu R, Hahn AM, Shackelford J, Pagano JS. Epstein- Barr virus BRLF1 inhibits transcription of IRF3 and IRF7 and suppresses induction of interferon-b. Virology. 2010;402:121-8.
139. Liang Q, Deng H, Sun C-W, Townes TM, Zhu F. Negative regulation of IRF7 activation by activating transcription factor 4 suggests a cross-regulation between the IFN responses and the cellular integrated stress responses. J Immunol. 2011;186: 1001-10.
140. Colina R, et al. Translational control of the innate immune response through IRF-7. Nature. 2008;452:323-8.
141. Zhang L, Pagano JS. Interferon regulatory factor 7 mediates activation of Tap-2 by Epstein-Barr virus latent membrane protein 1. J Virol. 2001;75:341-50.
142. Higgs R, et al. Self protection from anti-viral responses-Ro52 promotes degradation of the transcription factor IRF7 downstream of the viral toll-like receptors. PLoS ONE. 2010;5:e11776.
143. Kubota T, et al. Virus infection triggers SUMOylation of IRF3 and IRF7, leading to the negative regulation of type I interferon gene expression. J Biol Chem. 2008;283:25660-70.
144. Chang T-H, et al. Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLoS Pathog. 2009;5:e1000493.
145. Caillaud A, et al. Acetylation of interferon regulatory factor-7 by p300/CREB-binding protein (CBP)-associated factor (PCAF) impairs its DNA binding. J Biol Chem. 2002;277:49417-21.
146. Liang Q, et al. Tripartite motif-containing protein 28 is a small ubiquitin-related modifier E3 ligase and negative regulator of IFN regulatory factor 7. J Immunol. 2011;187:4754-63.
147. Kim H, Seed B. The transcription factor MafB antagonizes antiviral responses by blocking recruitment of coactivators to the transcription factor IRF3. Nat Immunol. 2010;11:743-50.
148. Yang K, et al. TRIM21 is essential to sustain IFN regulatory factor 3 activation during antiviral response. J Immunol. 2009; 182:3782-92.
149. Parvatiyar K, Barber GN, Harhaj EW. TAX1BP1 and A20 inhibit antiviral signaling by targeting TBK1-IKKi kinases. J Biol Chem. 2010;285:14999-5009.
150. Yang Y-K, et al. ARF-like protein 16 (ARL16) inhibits RIG-I by binding with its C-terminal domain in a GTP-dependent manner. J Biol Chem. 2011;286:10568-80.
151. Gabhann JN, et al. Absence of SHIP-1 results in constitutive phosphorylation of tank-binding kinase 1 and enhanced TLR3- dependent IFN-b production. J Immunol. 2010;184:2314-20.
152. Siednienko J, Gajanayake T, Fitzgerald KA, Moynagh P, Miggin SM. Absence of MyD88 results in enhanced TLR3-dependent phosphorylation of IRF3 and increased IFN-b and RANTES production. J Immunol. 2011;186:2514-22.
153. Verstrepen L, Verhelst K, van Loo G, Carpentier I, Ley SC, Beyaert R. Expression, biological activities and mechanisms of action of A20 (TNFAIP3). Biochem Pharmacol. 2010;80:2009-20.
154. Wang Y-Y, Li L, Han K-J, Zhai Z, Shu H-B. A20 is a potent inhibitor of TLR3- and Sendai virus-induced activation of NFjB and ISRE and IFN-b promoter. FEBS Lett. 2004;576:86-90.
155. Saitoh T, et al. A20 is a negative regulator of IFN regulatory factor 3 signaling. J Immunol. 2005;174:1507-12.
156. Zhao W, et al. Peroxisome proliferator-activated receptor c negatively regulates IFN-b production in toll-like receptor (TLR) 3- and TLR4-stimulated macrophages by preventing interferon regulatory factor 3 binding to the IFN-b promoter. J Biol Chem. 2011;286:5519-28.
157. Lin R, et al. Negative regulation of the retinoic acid-inducible gene I-induced antiviral state by the ubiquitin-editing protein A20. J Biol Chem. 2006;281:2095-103.
158. Ning S, Pagano JS. The A20 deubiquitinase activity negatively regulates LMP1 activation of IRF7. J Virol. 2010;84:6130-8.
159. Saitoh T, et al. Negative regulation of interferon-regulatory factor 3-dependent innate antiviral response by the prolyl isomerase Pin1. Nat Immunol. 2006;7:598-605.
160. Higgs R, Gabhann JN, Larbi NB, Breen EP, Fitzgerald KA, Jefferies CA. The E3 ubiquitin ligase Ro52 negatively regulates IFN-b production post-pathogen recognition by polyubiquitinmediated degradation of IRF3. J Immunol. 2008;181:1780-6.
161. Kong HJ, et al. Cutting edge: autoantigen Ro52 is an interferon inducible E3 ligase that ubiquitinates IRF-8 and enhances cytokine expression in macrophages. J Immunol. 2007;179:26-30.
162. Xiong H, et al. Ubiquitin-dependent degradation of interferon regulatory factor-8 mediated by Cbl down-regulates interleukin- 12 expression. J Biol Chem. 2005;280:23531-9.
163. Yu Y, Hayward GS. The ubiquitin E3 ligase RAUL negatively regulates type I interferon through ubiquitination of the transcription factors IRF7 and IRF3. Immunity. 2010;33:863-77.
164. Sears N, Sen GC, Stark GR, Chattopadhyay S. Caspase-8- mediated cleavage inhibits IRF-3 protein by facilitating its proteasome-mediated degradation. J Biol Chem. 2011;286: 33037-44.
165. Praefcke GJK, Hofmann K, Dohmen RJ. SUMO playing tag with ubiquitin. Trends Biochem Sci. 2011;37:23-31.
166. Denuc A, Marfany G. SUMO and ubiquitin paths converge. Biochem Soc Trans. 2010;38:34-9.
167. Ran Y, et al. SENP2 negatively regulates cellular antiviral response by deSUMOylating IRF3 and conditioning it for ubiquitination and degradation. J Mol Cell Biol. 2011;3:283-92.
168. Dastur A, Beaudenon S, Kelley M, Krug RM, Huibregtse JM. Herc5, an interferon-induced HECT E3 enzyme, is required for conjugation of ISG15 in human cells. J Biol Chem. 2006; 281:4334-8.
169. Wong JJY, Pung YF, Sze NS-K, Chin K-C. HERC5 is an IFNinduced HECT-type E3 protein ligase that mediates type I IFNinduced ISGylation of protein targets. Proc Natl Acad Sci. 2006;103:10735-40.
170. Lu G, et al. ISG15 enhances the innate antiviral response by inhibition of IRF-3 degradation. Cell Mol Biol (Noisy-le-grand) 2006;52:29-41.
171. Shi H-X, et al. Positive regulation of interferon regulatory factor 3 activation by Herc5 via ISG15 modification. Mol Cell Biol. 2010;30:2424-36.
172. Prinarakis E, Chantzoura E, Thanos D, Spyrou G. S-glutathionylation of IRF3 regulates IRF3-CBP interaction and activation of the IFN[beta] pathway. EMBO J. 2008;27:865-75.
173. Xu H-G, Ren W, Lu C, Zhou G-P. Characterization of the human IRF-3 promoter and its regulation by the transcription factor E2F1. Mol Biol Rep. 2010;37:3073-80.
174. Xu H-G, Ren W, Zou L, Wang Y, Jin R, Zhou G-P. Direct repression of the human IRF-3 promoter by E2F1. Immunogenetics. 2011;63:189-96.
175. Lim C-A, et al. Genome-wide mapping of RELA(p65) binding identifies E2F1 as a transcriptional activator recruited by NF-jB upon TLR4 activation. Mol Cell. 2007;27:622-35.
176. Li C, Ma L, Chen X. Interferon regulatory factor 3-CL, an isoform of IRF3, antagonizes activity of IRF3. Cell Mol Immunol. 2011;8:67-74.
177. Karpova AY, Ronco LV, Howley PM. Functional characterization of interferon regulatory factor 3a (IRF-3a), an alternative splice isoform of IRF-3. Mol Cell Biol. 2001;21:4169-76.
178. Marozin S, Altomonte J, Stadler F, Thasler WE, Schmid RM, Ebert O. Inhibition of the IFN-beta response in hepatocellular carcinoma by alternative spliced isoform of IFN regulatory factor-3. Mol Ther. 2008;16:1789-97.
179. Goh FG, Thomson SJP, Krausgruber T, Lanfrancotti A, Copley RR, Udalova IA. Beyond the enhanceosome: cluster of novel jB sites downstream of the human IFN-b gene is essential for lipopolysaccharide-induced gene activation. Blood. 2010;116: 5580-8.
180. Yount JS, Gitlin L, Moran TM, Lopez CB. MDA5 participates in the detection of paramyxovirus infection and is essential for the early activation of dendritic cells in response to Sendai virus defective interfering particles. J Immunol. 2008;180:4910-8.
181. Honda K, et al. IRF-7 is the master regulator of type-I interferon- dependent immune responses. Nature. 2005;434:772-7.
182. Carrigan SO, et al. IFN regulatory factor 3 contributes to the host response during Pseudomonas aeruginosa lung infection in mice. J Immunol. 2010;185:3602-9.